Drugs / GAd20-209-FSP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04041310 | Oct 2019 → Oct 2026 expected | cancer | Nouscom SRL | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAd20-209-FSP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04041310 ↗ |
| Route | Intramuscular | “Both Frame Shift Peptide (FSP) neoantigen-encoding genetic vaccines are administered intramuscularly” NCT04041310 ↗ |